Toogood Peter L
Lycera Corp., 1350 Highland Drive, Ann Arbor, MI, United States.
Bioorg Med Chem Lett. 2018 Feb 1;28(3):319-329. doi: 10.1016/j.bmcl.2017.12.044. Epub 2017 Dec 20.
Treatment of cancer by activation of an antitumor immune response is now a widely practiced and well-accepted approach to therapy. However, despite dramatic responses in some patients, the high proportion of unresponsive patients points to a considerable unmet medical need. Although antibody therapies have led the way, small molecule immuno-oncology agents are close behind. This perspective provides an overview of some of the many small molecule approaches being explored. It encompasses small molecule modulators of validated targets such as programed cell death 1 (PD-1) as well as novel approaches still to be proven clinically.
通过激活抗肿瘤免疫反应来治疗癌症如今已成为一种广泛应用且被普遍接受的治疗方法。然而，尽管部分患者有显著疗效，但无反应患者的高比例表明仍存在相当大的未满足医疗需求。尽管抗体疗法处于领先地位，但小分子免疫肿瘤药物也紧随其后。本综述概述了正在探索的众多小分子方法中的一些。它涵盖了已验证靶点（如程序性细胞死亡蛋白1，PD-1）的小分子调节剂以及仍有待临床验证的新方法。
